It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to danazol.
Temsirolimus is a CYP3A4 substrate and danazol is a moderate CYP3A4 inhibitor.
Danazol, USP is a synthetic steroid derived from ethisterone.
You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. Menstrual disturbances in the form of spotting, alteration of the timing of the cycle and amenorrhoea. Laboratory monitoring of the hematologic state should be considered. Danazol may cause an increase in carbamazepine.
Markedly impaired hepatic, renal, or cardiac function. It is important to prevent pregnancy while using this medication.
Ask your doctor before use if you are taking the following medications:
Liver enlargement can increase the risk of lactic acidosis.
Use of intranasal corticosteroids in susceptible individuals or in excess of recommended dosing may result in hypercorticism and adrenal suppression.
This benefit must be weighed against the potential toxicity of this drug when used without folate supplementation.
As a result you may be at an increased risk of having more side effects from the drug.
Anyone considering the use of antiepileptic drugs must balance this risk of suicide with the clinical need for the drugs.
This medicine can affect your menstrual cycle and you may stop having menstrual periods. Avoid coadministration of oral budesonide and danazol due to the potential for increased budesonide exposure. Gonadotrophins normally stimulate the production of sex hormones such as oestrogen and progestogen, which are responsible for body processes such as menstruation and ovulation. Before initiating therapy of fibrocystic breast disease with Danazol, carcinoma of the breast should be excluded.
Laboratory monitoring of the hematologic state should be considered. The total daily dosage of Danazol for fibrocystic breast disease ranges from 100 mg to 400 mg given in two divided doses depending upon patient response.